Immunosuppressive Drugs

Question 1

Block cytokine production,
inflammatory mediators, chemoattractants, and adhesion molecules; reduce macrophage function and alter leukocyte trafficking.

Answer 1

CORTICOSTEROIDS

Question 2

Maintenance immunosuppression; AR treatment (high doses)

Hypertension, diabetes mellitus with long-term use.

Answer 2

Corticosteroids

Question 3

Interfere with lymphocyte maturation and kill | proliferating cells.

Answer 3

Antimetabolites

Question 4

Maintenance immunosuppression.

Fewer side effects with newer agents like mycophenolate.

Answer 4

Antimetabolites

Question 5

Block T-cell signal transduction, impair
cytokine synthesis (e.g., IL-2), and inhibit T-cell growth and differentiation.

Answer 5

CALCINEURIN INHIBITORS

Question 6

Maintenance immunosuppression.

Potential nephrotoxicity and other toxicities.

Answer 6

CALCINEURIN INHIBITORS

Question 7

Target specific lymphocyte surface molecules (e.g., CD25, CD52) to inhibit T-cell activation or deplete lymphocytes.

Answer 7

Monoclonal antibodies

Question 8

Induction therapy; severe rejection episodes

Risk of anti-mouse antibody response; reduced with humanized antibodies.

Answer 8

Monoclonal antibodies

Question 9

Deplete circulating lymphocytes by targeting T cells (anti-T-cell antibody).

Answer 9

Polyclonal antibodies

Question 10

Induction therapy; severe rejection episodes

Risk of serum sickness due to foreign immunoglobulin.

Answer 10

Polyclonal antibodies